See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Activity of cefiderocol and comparator agents against difficult-to-treat resistant Acinetobacter baumannii-calcoaceticus complex isolates collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against difficult-to-treat resistant Acinetobacter baumannii-calcoaceticus complex isolates collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against difficult-to-treat resistant Pseudomonas aeruginosa collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against difficult-to-treat resistant Pseudomonas aeruginosa collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against global Isolates of Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2023)
Activity of cefiderocol and comparator agents against global Isolates of Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2023)
Activity of cefiderocol and comparator agents against isolates from hospitalized pediatric patients with pneumonia collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against isolates from hospitalized pediatric patients with pneumonia collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against pediatric isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022)
Activity of cefiderocol and comparator agents against pediatric isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022)
Activity of cefiderocol and comparator agents against uncommon Gram-negative isolates collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against uncommon Gram-negative isolates collected during 2020–2022 as part of the SENTRY antimicrobial surveillance program
You Are Viewing Congress Locations
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
SCCM 2024
IDWeek 2023
CHEST 2023
ESWI 2023
ISSX 2023
PAGE 2023
